Listeria monocytogenes : a promising vector for tumor immunotherapy.

Autor:	Ding YD; Medical College, Nanchang University, Nanchang, China., Shu LZ; Medical College, Nanchang University, Nanchang, China., He RS; Medical College, Nanchang University, Nanchang, China., Chen KY; Office of Clinical Trials Administration, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China., Deng YJ; Department of Pathology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China.; Tumor Immunology Institute, Nanchang University, Nanchang, China., Zhou ZB; Department of Pathology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China.; Tumor Immunology Institute, Nanchang University, Nanchang, China., Xiong Y; Department of General Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China., Deng H; Department of Pathology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China.; Tumor Immunology Institute, Nanchang University, Nanchang, China.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Oct 06; Vol. 14, pp. 1278011. Date of Electronic Publication: 2023 Oct 06 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1278011
Abstrakt:	Cancer receives enduring international attention due to its extremely high morbidity and mortality. Immunotherapy, which is generally expected to overcome the limits of traditional treatments, serves as a promising direction for patients with recurrent or metastatic malignancies. Bacteria-based vectors such as Listeria monocytogenes take advantage of their unique characteristics, including preferential infection of host antigen presenting cells, intracellular growth within immune cells, and intercellular dissemination, to further improve the efficacy and minimize off-target effects of tailed immune treatments. Listeria monocytogenes can reshape the tumor microenvironment to bolster the anti-tumor effects both through the enhancement of T cells activity and a decrease in the frequency and population of immunosuppressive cells. Modified Listeria monocytogenes has been employed as a tool to elicit immune responses against different tumor cells. Currently, Listeria monocytogenes vaccine alone is insufficient to treat all patients effectively, which can be addressed if combined with other treatments, such as immune checkpoint inhibitors, reactivated adoptive cell therapy, and radiotherapy. This review summarizes the recent advances in the molecular mechanisms underlying the involvement of Listeria monocytogenes vaccine in anti-tumor immunity, and discusses the most concerned issues for future research. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Ding, Shu, He, Chen, Deng, Zhou, Xiong and Deng.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu